Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.79)
# 3,750
Out of 4,761 analysts
29
Total ratings
26.09%
Success rate
-15.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Reiterates: Equal-Weight | $29 | $36.85 | -21.30% | 4 | Feb 12, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $11.66 | +28.64% | 2 | Jan 22, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $31 | $16.87 | +83.76% | 3 | Jan 21, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $36.81 | +63.00% | 2 | Jan 21, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Overweight | $140 | $92.25 | +51.76% | 2 | Jan 2, 2025 | |
| ELEV Elevation Oncology | Reiterates: Overweight | $5 | $0.61 | +723.18% | 2 | Dec 6, 2024 | |
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $5 | $1.17 | +327.35% | 2 | Nov 19, 2024 | |
| CPRX Catalyst Pharmaceuticals | Initiates: Overweight | $35 | $21.62 | +61.89% | 1 | Nov 18, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $51 | $21.85 | +133.41% | 1 | Nov 18, 2024 | |
| CCCC C4 Therapeutics | Initiates: Equal-Weight | $4 | $3.01 | +32.89% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $17.77 | +209.51% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $6 | $1.63 | +268.10% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $9.52 | +215.13% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.28 | +915.63% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $14.88 | +68.01% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.45 | +1,010.37% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.24 | +792.86% | 1 | May 14, 2024 |
Exelixis
Feb 12, 2025
Reiterates: Equal-Weight
Price Target: $29
Current: $36.85
Upside: -21.30%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $11.66
Upside: +28.64%
Nurix Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $31
Current: $16.87
Upside: +83.76%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $36.81
Upside: +63.00%
Blueprint Medicines
Jan 2, 2025
Reiterates: Overweight
Price Target: $140
Current: $92.25
Upside: +51.76%
Elevation Oncology
Dec 6, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.61
Upside: +723.18%
Actinium Pharmaceuticals
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.17
Upside: +327.35%
Catalyst Pharmaceuticals
Nov 18, 2024
Initiates: Overweight
Price Target: $35
Current: $21.62
Upside: +61.89%
IDEAYA Biosciences
Nov 18, 2024
Initiates: Overweight
Price Target: $51
Current: $21.85
Upside: +133.41%
C4 Therapeutics
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $3.01
Upside: +32.89%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $17.77
Upside: +209.51%
Nov 8, 2024
Initiates: Overweight
Price Target: $6
Current: $1.63
Upside: +268.10%
Nov 8, 2024
Initiates: Overweight
Price Target: $30
Current: $9.52
Upside: +215.13%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.28
Upside: +915.63%
Aug 6, 2024
Reiterates: Overweight
Price Target: $25
Current: $14.88
Upside: +68.01%
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.45
Upside: +1,010.37%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.24
Upside: +792.86%